HPV Vaccine for Genital Warts

Recruiting in Palo Alto (17 mi)

Overseen ByAyan Kusari, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: University of California, San Francisco

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial will test if injecting genital warts with the Gardasil 9 vaccine can reduce their size and number. The study involves patients with genital warts who will receive the vaccine directly into their warts. Researchers hope that this will help the body's immune system fight off the virus causing the warts. Gardasil 9 is a vaccine that has been shown to be highly effective in preventing HPV-related diseases, including genital warts.

Eligibility Criteria

This trial is for adults over 18 with genital warts, specifically at least three warts larger than 3mm. Participants must not be on immune-suppressing drugs or have conditions affecting their immune system, and they can't be pregnant or planning to become pregnant soon. They also shouldn't have had an HPV vaccine before or be allergic to yeast and vaccine components.

Inclusion Criteria

I have been diagnosed with genital warts, with at least 3 warts each bigger than 3mm.

Exclusion Criteria

I am not on immune suppressive medications nor do I have conditions affecting my immune system.

I have received an HPV vaccine in the past.

Participant Groups

The study is testing the effects of injecting small amounts of Gardasil 9, a nonavalent human papillomavirus vaccine, directly into genital warts to see if it helps treat them.

1Treatment groups

Experimental Treatment

Group I: Intralesional injection of nonavalent human papillomavirus vaccineExperimental Treatment1 Intervention

Single-arm, open-label study. Intervention consists of intralesional injection of nonavalent human papillomavirus vaccine at 0 and 4 weeks.